Michigan Life Sciences Establishments Grow at Rate Higher Than the National Average, Says New Report

Tenth Biennial TEConomy/BIO Report Released ANN ARBOR, MI, UNITED STATES, November 8, 2022 /EINPresswire.com/ — The Biotechnology Innovation Organization (BIO) released its tenth biennial report “The U.S. Bioscience Industry: Fostering Innovation and Driving America’s Economy Forward” with new employment and economic impact data (through 2021) for the nation’s biosciences industry The report, produced in partnership with TEConomy,…

Read More

Thermo Fisher Scientific weighs in on the need for more disruptive technologies to advance healthcare in India during the Conference on Application of New-age technologies in Diagnostics

7th Oct 2022, New Delhi: Thermo Fisher Scientific, the world leader in serving science, recently participated in a conference on the Application of New-age Technologies in Diagnostics organized by the Confederation of Indian Industry (CII) Northern Regional Committee on Diagnostics and Technology.   CII is a non-government, not-for-profit, industry-led organization, that is engaged in creating…

Read More

Hospitals and pharmacies profit as 340B drives up patients’ drug costs

Original Source   The federal 340B Drug Pricing Program is starting to get a great deal of attention—for all the wrong reasons. The program was started in 1992 with the goal of allowing hospitals and clinics that work with underserved communities to provide outpatient prescription drugs to patients at deep discounts. Now, after 30 years,…

Read More

Biomanufacturing to get a boost from Biden’s new executive order

US President Joe Biden signed an executive order on Monday that will “help expand U.S. biomanufacturing and reduce reliance on China,” according to Bloomberg. The executive order will launch a National Biotechnology and Biomanufacturing Initiative that will accelerate biotechnology innovation and grow America’s bioeconomy across multiple sectors, including a range of industries, including health, agriculture, and energy, the White…

Read More

Efforts at value-based care focus on patients’ needs

Original Source What is the value of a treatment? As of July, the U.S. government has given out close to 600 million doses of COVID-19 vaccines at prices that ranged between $15-$20 per dose, which means they spent $10-$12 billion on shots. Research shows that, as of March, the U.S. vaccination program saved 2 million lives and $900 billion in…

Read More

Price Controls Would Devastate Drug Development, Patient Access, Says New Analysis

Original Source: https://vitaltransformation.com/2022/07/build-back-better-act-total-market-impact-of-price-controls-in-medicare-parts-d-and-b/ Build Back Better Act Total market impact of price controls in Medicare parts D and B The Executive Summary The Build Back Better Act (BBBA) is designed to allow the US Government to ‘negotiate’ pricing under a set framework of reductions based upon the amount of time a drug has spent on…

Read More

New Funding Opportunity from the NIH: Small Business Transition Grant For Early Career Scientists

The National Cancer Institute (NCI) recently released a new funding opportunity for biotech companies and university researchers! The new Small Business Transition Grant funds the translation of technology from university to small business, as well as the transition of early career researchers from academia to industry. This award uses the Small Business Technology Transfer (STTR)…

Read More

PE-backed Angstrom Technology pursues acquisitions to fill cleanroom market gaps

Original Source WALKER — A couple of recent strategic acquisitions should further prepare cleanroom designer and builder Angstrom Technology Ltd. for overseas projects as the company continues a private equity-backed string of acquisitions. After New York City private equity firm ASGARD Partners & Co. acquired a controlling interest in Angstrom in November 2020, Angstrom has persued deals to expand…

Read More

FDA Urges Companies to be ’Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

Original Source Today, the U.S. Food and Drug Administration finalized guidance to help companies prepare to quickly and effectively remove violative products from the market. The guidance describes steps companies should take, before a recall is necessary, to develop recall policies and procedures that include training, planning and record-keeping to reduce the time a recalled…

Read More

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

CIBINQO is a once-daily oral treatment with proven efficacy to manage symptoms for adults who have not yet found relief with current options NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of…

Read More